A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SINGLE ASCENDING ORAL DOSES OF PF-08057418 IN HEALTHY ADULT PARTICIPANTS

Summary

The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults. Everyone who participates in this study will receive the study medicine. The study medicine may be given as a solution or as a tablet. Participants will be dosed once a week for 5 weeks. The investigator will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe. Participants will be involved in this study for up to 13 weeks from screening to follow-up visit. Participants stay in the study clinic for the 5 week dosing duration of the study, with two follow-up visits subsequently, either in person or by telephone call.

Eligibility

Age range

18–60 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  PF-08057418

  solution or tablet (fasted/fed)

• Other
  Placebo (A placebo does not have any medicine in it but looks just like the medicine being studied.)

  solution or tablet (fasted/fed)

Location